This article is more than 5 years old. Information may no longer be current.

Optos announces collaborations in Alzheimer’s disease, AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Optos Plc, a subsidiary of Nikon Corp., Japan, announced a clinical alliance with Amydis Inc. to develop an eye test to detect Alzheimer’s disease and exclusive distribution agreements in Europe and Australia with MacuLogix and LumiThera for their age-related macular degeneration products.

Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina that can be visualized with Optos’ Optomap ultra-widefield retinal imaging devices to diagnose Alzheimer’s disease, according to a press release from Optos.

These compounds bind to specific biomarkers in the retina and fluoresce, making them visible with an Optomap retinal camera, Optos said.

Optos also announced exclusive distribution agreements in Europe and Australia with MacuLogix, for its AdaptDx, a dark adaptometer that can be used to detect AMD at a subclinical stage, and with LumiThera, for its Valeda Light Delivery System for treating dry AMD using photobiomodulation.